Education Qualifications: MD, PhD, FHKAM, FHKCP, FRCP
Professor Angela Wang is currently Clinical Professor with Medicine Academic Clinical Programme at the SingHealth Duke-NUS Academic Medical Centre and Senior Consultant at the Department of Renal Medicine, Singapore General Hospital. She was formerly a staff nephrologist and clinician scientist at the Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China. Angela has a strong track record in both clinical and academic medicine in nephrology. She has strong experience in international clinical practice guidelines (CPG) development and is world recognized for her research in cardiovascular-kidney-metabolic health, chronic kidney disease-mineral bone disease (CKD-MBD), biomarkers research for personalized cardiovascular-kidney-metabolic care, peritoneal dialysis and translational nutrition research in kidney disease. Her latest research endeavors are in clinical trials and innovations to improve the outcomes of patients with kidney diseases, precision medicine in cardiovascular-kidney-metabolic care as well as preventive kidney medicine. She is the Lead Principal Investigator of OPERA, PROCEED and PROOF Trials and also an Executive Member of POSIBIL6-ESKD Trials.
She actively contributes to international societies by being the current Councilor of the International Society of Nephrology (ISN), Chair of the ISN Education Working Group and Chair of the ISN North and East Asia Regional Board. She is the Past President of the International Society of Renal Nutrition and Metabolism (ISRNM). She co-chaired the Global Kidney Nutrition Care Atlas, a joint initiative between ISRNM and ISN with an aim to advance global kidney nutrition care. She is a Council member of the International Society of Peritoneal Dialysis (ISPD) and a member of the ISN Cardio-Renal Roadmap, a collaborative with the European Society of Heart Failure (ESHF), Renal Physician Association (RPA), American Society of Preventive Cardiology (ASPC) and Kidney Disease Improving Global Outcomes (KDIGO) aiming to advance global cardio-kidney care. She was an Executive Committee member of Kidney Disease Improving Global Outcomes (KDIGO). She is also a Core Committee Member of ISN-Advancing Clinical Trial (ACT) with an aim to drive global clinical trials conduct in kidney diseases and an Executive Committee Member of the Standardized Outcomes in Nephrology (SONG) Initiative.
She has served as a workgroup member of many international CPG including the latest KDIGO anaemia guidelines update in CKD (2022 -), the Joint ISPD and Global Renal Exercise Network (GREX) Practice Recommendations on Physical Activity and Exercise in PD in 2021, Kidney Disease Outcome Quality Initiative (KDOQI) Nutrition Guidelines in CKD in 2020, the ISPD Prescribing High Quality Goal-Directed PD Guidelines in 2020, and KDIGO CKD-Mineral Bone Disease (MBD) CPG in 2009.
She chaired the ISPD Cardiovascular and Metabolic Guidelines for Adult Peritoneal Dialysis Patients in 2015 and is the Chair of the First Joint ISRNM and ISPD Practice Recommendations on Nutrition Management in Peritoneal Dialysis Patients (2023- ). Angela is also the co-chair of KDIGO CKD-MBD 2017 guidelines implementation Asia summit in 2017 and KDIGO Diabetes and Blood pressure in CKD Asia-Pacific guidelines implementation summit in 2024.
She has received several prestigious international awards in recognition of her work in cardiovascular-metabolic-nutrition complications in kidney disease including the Thomas Addis Award, a lifetime award of the International Society of Renal Nutrition and Metabolism in Dec 2022, the Joel D. Kopple Award from the United States National Kidney Foundation in April 2018 in recognition of her contributions in the field of renal nutrition and metabolism. She has received the Travelling Lecturer Award of the Asia Pacific Federation of Clinical Biochemistry in 2011/2012 and the John F. Maher Award of the ISPD in 2006 in recognition of her research work in cardiac biomarkers, cardiovascular disease and peritoneal dialysis, respectively. She was invited to give Dr VN Acharya’s Oration at the 1st Annual Chapter of Women in Nephrology (WIN) -International Conference 2022.
She has published over 230 papers, 15 book chapters and delivered over 200 invited lectures at international and regional conferences. She currently serves on the editorial boards of several leading kidney journals including: Kidney Int, American Society of Nephrology (ASN) Journals, Nephrol Dial Transplant (Theme Editor), Nephron Clinical Practice (Associate Editor), J Renal Nutrition, J Diabetes, etc and was previously Associate Editor of Am J Kidney Dis. She is also the current Editor-in-Chief of European Medical Journal (EMJ)-Nephrology.
Professional Appointments and Committee Memberships:
- Clinical Professor, Duke-NUS Medical School
- Senior Consultant, Department of Renal Medicine, Singapore General Hospital
Awards:
- Thomas Addis Award, International Society of Renal Nutrition and Metabolism (2022)
- Dr VN Acharya’s Oration, 1st Annual Chapter of Women in Nephrology (WIN)-International Conference (2022)
- Joel D. Kopple Award, United States National Kidney Foundation (NKF) (2018)
- Asia Pacific Federation of Clinical Biochemistry Travelling Lecturer Award (2011/2012)
- John Maher Award, International Society of Peritoneal Dialysis (2006)
Leadership positions / roles in Education:
- Councilor of the International Society of Nephrology (ISN) (2023 -)
- Chair of the ISN Education Working Group (2023 -)
- Chair of the ISN North and East Asia Regional Board (2023 -)
- Past President of the International Society of Renal Nutrition and Metabolism (ISRNM) (2023 -)
- Member of the ISN Cardio-Renal Roadmap (2022 -)
- Co-chair, Global Kidney Nutrition Care Atlas – a Joint Initiative of ISN Global Kidney Care Atlas and ISRNM (2018-2022)
- Chair, Scientific Program Committee of the 20th Congress of the ISRNM in 2022.
- Co-convenor of the joint ISRNM and International Federation of Kidney Foundation-World Kidney Alliance (IFKF-WKA) initiative ‘Renal Nutrition, Diet and World Kidney Recipes’ (2021 - 2023)
- Core Committee Member of ISN- Advancing Clinical Trial (ACT) Working group (2018 -)
- Steering member, CKD Prognosis Consortium Phase 6 (2018 -)
- Council member of the International Society of Peritoneal Dialysis (ISPD) (2016 -)
- Board member (2011-2015) and Executive Committee member (2015 -2017) of KDIGO
- Executive Committee Member of the Standardized Outcomes in Nephrology (SONG) Initiative (2016 -)
- Subcommittee Chair, ISPD Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) (2012 -)
- Secretary, Hong Kong Nephrology Group (2022 -)
Email : angela.wang@duke-nus.edu.sg
angela.wang.y.m@singhealth.com.sg
Selected Publications:
1. Wang AY, Tang TK, Yau YY, Lo WK. Impact of parathyroidectomy versus oral cinacalcet on bone mineral density in patients on peritoneal dialysis with advanced secondary hyperparathyroidism: The PROCEED pilot randomized trial. Am J Kidney Dis 2024;83(4):456-466
2. Wang AY, Afsar RE, Sussman-Dabach EJ, White J, Mclaughlin H, Ikizler TA. Vitamins Use in Patients with CKD: Benefit or Pill Burden? Am J kidney Dis (Invited Review) 2023;83(3):370-385.
3. Wang AY, Okpechi IG, Ye F, Kovesdy CP, Brunori G, Burrowes JD, Campbell K, Damster S, Fouque D, Friedman A, Garibotto G, Guebre-Egzuabher F, Harris DC, Iseki K, Jha V, Jindal K, Kalantar-Zadeh K, Kistler B, Kopple JD, Kuhlmann M, Lunney M, Denise Mafra D, Malik C, Moore LW, Price SR, Steiber A, Tonelli M, Wanner C, ter wee P, Levin A, Johnson DW, Bello AK. Assessing Global Kidney Nutrition Care. Clin J Am Soc Nephrol 2022;17:38-52
4. Wang AY, Lo WK, Cheung SC, Tang TK, Yau YY, Lang BH. Parathyroidectomy versus Oral Cinacalcet on Cardiovascular Parameters in Peritoneal Dialysis Patients with Advanced Secondary Hyperparathyroidism (PROCEED): A Randomized Trial. Nephrol Dial Transplant 2023;38(8):1823-183
5. Sarnak MJ, Auguste BL, Brown E, Chang AR, Chertow GM, Hannan M, Herzog CA, Nadeau-Fredette AC, Tang WHW, Wang AY, Weiner DE, Chan CT; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Hypertension; and Council on Lifestyle and Cardiometabolic Health. Cardiovascular Effects of Home Dialysis Therapies: A Scientific Statement from the American Heart Association. Circulation 2022;146(11):e146-e164
6. Flythe JE, Chang TI, Gallagher MP, Lindley E, Madero M, Sarafidis PA, Unruh ML, Wang AY, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC, Polkinghorne KR; Conference Participants. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020;97:861-876
7. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, Fouque D, Friedman AN, Ghaddar S, Goldstein-Fuchs DJ, Kaysen GA, Kopple KA, Teta D, Wang AY, Cuppari L. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis 2020;76(3 Suppl 1):S1-S107
8. Wang AY, Brimble KS, Brunier G, Holt S, Jha V, Johnson DW, Kang SW, Kooman J, Lambie M, McIntyre C, Mehrotra R, Pecoits-Filho R. ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors. Perit Dial Int 2015;35:379-387
9. Wang AY, Wong CK, Yau YY, Wong S, Chan IH, Lam CW. Skin Autofluorescence associates with vascular calcification in chronic kidney disease. Arterioscler Thromb Vasc Biol 2014;34:1784-1790
10. Cai QZ, Lu XZ, Lu Y, Wang AY. Longitudinal Changes of Cardiac Structure and Function in CKD (CASCADE Study). J Am Soc Nephrol 2014;25:1599-1608
11. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CWK, Yu CM. Oral paricalcitol treatment on left ventricular mass and function in stages 3 - 5 chronic kidney disease patients with cardiac hypertrophy (OPERA Study): a randomized controlled trial. J Am Soc Nephrol 2014;25:175-186
12.Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic Kidney Disease: Global Dimension and Perspectives. The Lancet 2013;382:260-272 (Invited Review)
13.Wang AY, Wang M, Lam CWK, Chan HIS, Lui SF, Sanderson JE. Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. Am J Kidney Dis 2013;61:975-983
14.Ikizler AT, Cano NJ, Franch HA, Fouque D, Himmelfarb J, Kalantar-Zadeh K, Kuhlmann M, Stenvinkel P, TerWee P, Teta D, Wang AY, Wanner C. Prevention and Treatment of Protein Energy Wasting in Chronic Kidney Disease Patients: A joint statement from the International Society of Renal Nutrition and Metabolism. Kidney Int 2013;84:1096-1107
15.Wang AY, Lam CW, Chan HS, Wang M, Lui SF, Sanderson JE. Sudden cardiac death in end-stage renal disease patients: A 5-year prospective analysis. Hypertension 2010;56:210-216
16.Wang AY, Wang M, Lam CW, Chan IH, Sanderson JE. LV filling pressure by Doppler echocardiography in end-stage renal disease. Hypertension 2008;52:107-114
17. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE. N-terminal Pro-Brain Natriuretic Peptide: An Independent Risk Predictor of Cardiovascular Congestion, Mortality and Adverse Cardiovascular Outcomes in Chronic Peritoneal Dialysis Patients. J Am Soc Nephrol 2007;18:321-330
18. Wang AY. The importance of residual renal function in dialysis patients. Kidney Int (Invited Review) 2006;69(10):1726-1732
19.Wang AY, Wang M, Woo J, Lam CK, Lui SF, Li PK, Sanderson JE. Inflammation, residual kidney function and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-2194
20. Wang AY, Wang M, Woo J, Lam CK, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study.J Am Soc Nephrol 2003;13:159-168